Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 12/20 | 0.42 |
| ▸ | DRD2 | P14416 | 10/20 | 0.42 |
| ▸ | HTR1A | P08908 | 8/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 3/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4588498 | 0.99 | DRD4 (0.41) | DRD4DRD2HTR1APARP1SIGMAR1 | |
| SCHEMBL6437677 | 0.81 | SIGMAR1 (0.52) | DRD4DRD2PARP1SIGMAR1DRD3 | |
| SCHEMBL3453460 | 0.80 | HRH3 (0.40) | DRD4DRD2HTR1APARP1SIGMAR1 | |
| SCHEMBL6589037 | 0.80 | SIGMAR1 (0.44) | DRD4DRD2HTR1APARP1SIGMAR1 | |
| SCHEMBL6543298 | 0.79 | DRD4 (0.38) | DRD4DRD2HTR1APARP1SIGMAR1 | |
| SCHEMBL1138726 | 0.78 | SIGMAR1 (0.47) | DRD4DRD2HTR1APARP1SIGMAR1 | |
| SCHEMBL4589884 | 0.76 | DRD4 (0.40) | DRD4DRD2HTR1ASIGMAR1KCNH2 | |
| SCHEMBL4588233 | 0.74 | PPARG (0.53) | DRD2HTR1APARP1PPARGPPARA | |
| SCHEMBL4589196 | 0.74 | DRD4 (0.57) | DRD4DRD2HTR1ASIGMAR1DRD3 | |
| Hydrochloric Acid SCHEMBL4587862 | 0.73 | PPARG (0.53) | DRD2HTR1APARP1PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0979079-B1 | USE OF TETRAHYDROPYRIDINE DERIVATIVES TO PREPARE MEDICINES FOR TREATING DISEASES CAUSING DEMYELINATION | SANOFI SYNTHELABO (FR) | 2004-06-16 | — | — | EP | claimed |
| US-6344464-B1 | Use of tetrahydropyridine derivatives to prepare medicines for treating diseases causing demyelination | SANOFI-SYNTHELABO (FR) | 2002-02-05 | — | — | US | claimed |
| EP-0950048-B1 | 1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES FOR TREATING ALZHEIMER'S DISEASE | SANOFI SYNTHELABO (FR) | 2001-06-27 | — | — | EP | claimed |
| WO-2000051608-A1 | 3-THIENYL AND 3-FURANYL PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | claimed |
| US-6034090-A | 1-Phenylalkyl-1,2,3,6-tetrahydropyridines for treating Alzheimer's disease | SANOFI-SYNTHLABO (FR) | 2000-03-07 | — | — | US | claimed |
| CN-1240427-A | 1-phenylalkyl-1,2,3,6-tetrahydropyridines for treating alzheimer's disease | SANOFI SA (FR) | 2000-01-05 | — | — | CN | claimed |
| US-7320982-B2 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-β 1 | SANOFI-AVENTIS (FR) | 2008-01-22 | — | — | US | disclosed |
| US-20040157868-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-beta 1 | SANOFI-AVENTIS (FR) | 2004-08-12 | — | — | US | disclosed |
| EP-0979079-B1 | USE OF TETRAHYDROPYRIDINE DERIVATIVES TO PREPARE MEDICINES FOR TREATING DISEASES CAUSING DEMYELINATION | SANOFI SYNTHELABO (FR) | 2004-06-16 | — | — | EP | disclosed |
| US-6693118-B2 | E.G., 1-(2-(6,7-METHYLENEDIOXYNAPHTH-2-YL)-ETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE AND 1-2-(4-CYCLOHEXENYLPHENYL)-ETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6 -TETRAHYDROPYRIDINE; apoptosis inhibition; treatment of graft rejection or of acute or chronic rheumatoid arthritis | SANOFI-SYNTHELABO (FR) | 2004-02-17 | — | — | US | disclosed |
| CN-1129579-C | 1-phenylalkyl-1, 2,3, 6-tetrahydropyridines for treating alzheimer's disease | SANOFI SYNTHELABO (FR) | 2003-12-03 | — | — | CN | disclosed |
| EP-1017385-B1 | USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-beta 1 | SANOFI SYNTHELABO (FR) | 2003-07-16 | — | — | EP | disclosed |
| US-20020091143-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicament s acting upon TGF-beta 1 | SANOFI-AVENTIS (FR) | 2002-07-11 | — | — | US | disclosed |
| EP-1017385-A1 | USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-beta 1 | SANOFI-SYNTHELABO (FR) | 2000-07-12 | — | — | EP | disclosed |
| EP-0979079-A1 | USE OF TETRAHYDROPYRIDINE DERIVATIVES TO PREPARE MEDICINES FOR TREATING DISEASES CAUSING DEMYELINATION | SANOFI-SYNTHELABO (FR) | 2000-02-16 | — | — | EP | disclosed |
| CN-1240427-A | 1-phenylalkyl-1,2,3,6-tetrahydropyridines for treating alzheimer's disease | SANOFI SA (FR) | 2000-01-05 | — | — | CN | disclosed |
| EP-0950048-A1 | 1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES FOR TREATING ALZHEIMER'S DISEASE | SANOFI-SYNTHELABO (FR) | 1999-10-20 | — | — | EP | disclosed |
| WO-1998053821-A1 | USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-β1 | SANOFI-SYNTHELABO (FR) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998048802-A1 | USE OF TETRAHYDROPYRIDINE DERIVATIVES TO PREPARE MEDICINES FOR TREATING DISEASES CAUSING DEMYELINATION | SANOFI-SYNTHELABO (FR) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998025903-A1 | 1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES FOR TREATING ALZHEIMER'S DISEASE | SANOFI (FR) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091143-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicament s acting upon TGF-beta 1 | TGFB1, TGFBR1, TGFB2 | DRD4 2423/4885DRD2 2564/4885HTR1A 366/4885 |
| US-20040157868-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-beta 1 | TGFB1, TGFBR1, TGFB2 | DRD4 2867/4885DRD2 2854/4885HTR1A 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.